ArticleExperimental and therapeutic medicine2016
Separation of cordycepin from
Article in Experimental and therapeutic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Alkaloid-based nanodrug delivery systems: An emerging strategy against drug-resistant bacterial wound infections.International journal of pharmaceutics: X · 2026Review
- The Velvet protein vea: a key positive regulator of growth and cordycepin biosynthesis in Cordyceps militaris.Microbial cell factories · 2025Article
- Reconstruction of a Genome-Scale Metabolic Model forInternational journal of molecular sciences · 2025Article
- Immunopharmacological Insights intoCurrent pharmaceutical design · 2025Review
- Efficient de novo production of bioactive cordycepin by Aspergillus oryzae using a food-grade expression platform.Microbial cell factories · 2023Article
- Enhanced production of cordycepin under solid-state fermentation of Cordyceps militaris by using combinations of grains/substrates.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Cytotoxic activity of cordycepin produced by marine-derived fungus Emericella sp. against HT29 human colon cancer cell lines.Archives of microbiology · 2023Article
- Nutritional Profile Changes in an Insect-Fungus Complex ofFoods (Basel, Switzerland) · 2023Article
- Transcriptome and metabolome profiling unveils the mechanisms of naphthalene acetic acid in promoting cordycepin synthesis inFrontiers in nutrition · 2023Article
- Antimicrobial, antioxidant, anti-inflammatory, and cytotoxic activities of Cordyceps militaris spent substrate.PloS one · 2023Article
- Dynamic Genome-Wide Transcription Profiling and Direct Target Genes of CmWC-1 Reveal Hierarchical Light Signal Transduction inJournal of fungi (Basel, Switzerland) · 2022Article
- Biomass and Cordycepin Production by the Medicinal MushroomJournal of fungi (Basel, Switzerland) · 2021Review
- A study of the aphrodisiac properties ofVeterinary world · 2021Article
- Evaluation of Anti-Biofilm Capability of Cordycepin AgainstInfection and drug resistance · 2021Article
- Transcriptomic Responses ofFrontiers in nutrition · 2021Article
- Transcriptome Analysis Reveals the Flexibility of Cordycepin Network inFrontiers in microbiology · 2020Article
- Cordycepin Isolated fromMolecules (Basel, Switzerland) · 2019Article
- Xanthine Oxidase Inhibitory Potential, Antioxidant and Antibacterial Activities ofMedicines (Basel, Switzerland) · 2019Article
- Efficient CRISPR-Cas9 Gene Disruption System in Edible-Medicinal MushroomFrontiers in microbiology · 2018Article
- Development of High Cordycepin-ProducingMycobiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cordycepin exhibits various bio-activities, including anticancer, antibacterial, antiviral and immune regulation activities, and is a significant focus of research. However, the preparation of high-purity cordycepin remains challenging. Also, the molecular target with which cordycepin interacts to cause an antibacterial effect remains unknown. In the present study, cordycepin was prepared by preparative high-performance liquid chromatography (prep-HPLC) and the purity obtained was 99.6%, indicating that this technique may be useful for the large-scale isolation of cordycepin in the future. The results of computational molecular docking analysis indicated that the interaction energy between cordycepin and NAD+-dependent DNA ligase (LigA) was lower than that between cordycepin and other common antibacterial targets. The highly pure cordycepin obtained by prep-HPLC demonstrated inhibitory activity against LigA from various bacteria
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.